MX2021012386A - Proteínas de union triespecíficas, métodos y usos de las mismas. - Google Patents

Proteínas de union triespecíficas, métodos y usos de las mismas.

Info

Publication number
MX2021012386A
MX2021012386A MX2021012386A MX2021012386A MX2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A
Authority
MX
Mexico
Prior art keywords
binding
binding proteins
polypeptide
binds
proteins
Prior art date
Application number
MX2021012386A
Other languages
English (en)
Spanish (es)
Inventor
Ronnie Wei
Huawei Qiu
Béatrice Cameron
Tarik Dabdoubi
Cendrine Lemoine
Joerg Birkenfeld
Zhi- Yong YANG
Gary J Nabel
Ling Xu
Lan Wu
Edward Seung
Catherine Prades
Joerg Regula
Zhen Xing
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021012386A publication Critical patent/MX2021012386A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021012386A 2019-04-09 2020-04-08 Proteínas de union triespecíficas, métodos y usos de las mismas. MX2021012386A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831572P 2019-04-09 2019-04-09
EP19306261 2019-10-02
PCT/US2020/027320 WO2020210392A1 (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Publications (1)

Publication Number Publication Date
MX2021012386A true MX2021012386A (es) 2022-01-18

Family

ID=72751423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012386A MX2021012386A (es) 2019-04-09 2020-04-08 Proteínas de union triespecíficas, métodos y usos de las mismas.

Country Status (13)

Country Link
EP (1) EP3953388A1 (ja)
JP (1) JP2022527994A (ja)
KR (1) KR20210149141A (ja)
CN (1) CN113950484A (ja)
AU (1) AU2020272839A1 (ja)
BR (1) BR112021019915A2 (ja)
CA (1) CA3136821A1 (ja)
CO (1) CO2021014918A2 (ja)
IL (1) IL286929A (ja)
MX (1) MX2021012386A (ja)
SG (1) SG11202111012QA (ja)
TW (1) TW202104261A (ja)
WO (1) WO2020210392A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024077118A2 (en) * 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI803876B (zh) * 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2016033690A1 (en) * 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
PE20171764A1 (es) * 2015-01-23 2017-12-21 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
WO2016205531A2 (en) * 2015-06-17 2016-12-22 Genentech, Inc. Anti-her2 antibodies and methods of use
BR112018008011A2 (pt) 2015-10-25 2018-10-30 Sanofi proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
CN117964758A (zh) * 2017-10-10 2024-05-03 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
US11530268B2 (en) * 2018-10-09 2022-12-20 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection

Also Published As

Publication number Publication date
JP2022527994A (ja) 2022-06-07
SG11202111012QA (en) 2021-11-29
CO2021014918A2 (es) 2021-11-19
AU2020272839A1 (en) 2021-12-02
TW202104261A (zh) 2021-02-01
CA3136821A1 (en) 2020-10-15
CN113950484A (zh) 2022-01-18
EP3953388A1 (en) 2022-02-16
KR20210149141A (ko) 2021-12-08
BR112021019915A2 (pt) 2021-12-07
WO2020210392A1 (en) 2020-10-15
IL286929A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
WO2017180913A3 (en) Trispecific and/or trivalent binding proteins
MX2022014631A (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih.
HRP20210041T1 (hr) Kovalentno vezana diatijela koja imaju imunoreaktivnost s pd-1 i lag-3, i postupci njihove uporabe
WO2018134235A8 (en) Improved serum albumin binders
MX2023003630A (es) Aglutinantes de albumina de suero mejorados.
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
MX2019008536A (es) Aglutinantes de albumina serica mejorados.
MY164906A (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
WO2019074973A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
JP2017526632A5 (ja)
MX2021007947A (es) Terapeuticos de anticuerpo que se unen a ctla4.
MX2019003350A (es) .anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
MD3353212T2 (ro) Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora
PH12020500137A1 (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
PH12014501818A1 (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
EP4257193A3 (en) Trispecific and/or trivalent binding proteins
MX2021012386A (es) Proteínas de union triespecíficas, métodos y usos de las mismas.
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2021012384A (es) Proteínas de union triespecíficas y/o trivalentes que utilizan el formato de dominio variable cruzado doble (codv) para el tratamiento de la infección por vih.
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum